Introduction
Muscular dystrophies are clinically and molecularly heterogeneous genetic diseases characterised by a primary wasting of skeletal muscle that compromises patient mobility. This is caused, in the majority of the cases, by the lack of one of several proteins located either at the plasma membrane or, less frequently, within internal membranes. Such deficiency increases the probability of damage during contraction, and eventually leads to fibre degeneration, accompanied by severe local inflammation with infiltration of immune-competent cells (Emery, 2002) . Inflammation is followed by sclerosis, thus starting a vicious circle that reduces oxygen supply and increases the likelihood of degeneration for surviving and regenerated fibres (Emery, 2002) . In the most severe forms, such as Duchenne muscular dystrophy, regeneration is progressively exhausted, and skeletal muscle is replaced by fat and fibrous tissue. This condition leads to progressive muscle weakness and eventually paralysis, ultimately causing death by respiratory and/or cardiac failure (Emery, 2002) . Although the underlying molecular defects are now known, there is still no available satisfactory therapy.
The current therapies, based on corticosteroid administration, provide only temporary improvements and are associated with severe side-effects (Manzur et al., 2004) . The other pharmacological strategies attempted so far, including administration of protease inhibitors, and drugs that regulate calcium homeostasis or act on protein and lipid metabolism, have yielded no favourable outcomes in clinical trials and did not enter the clinical practice (Skuk et al., 2002) .
In the past few years experimental approaches offering an alternative to classical pharmacological treatments have been developed, among which the injection of myogenic stem cells and gene therapy with adeno-associated viral vectors appear to hold particular promise . Significant restoration of muscle structure and function in the ␣-sarcoglycan (␣SG)-null mouse model of muscular dystrophy have been obtained using mesoangioblasts, a population of vessel-associated, mesoderm stem cells that express angioblast and mesoderm markers (Minasi et al., 2002; Sampaolesi et al., 2003) . Although promising, this cell therapy is still far from yielding a complete reconstitution of the skeletal muscle structure. The main reasons for the only partial effect of Muscular dystrophies are characterized by primary wasting of skeletal muscle for which no satisfactory therapy is available. Studies in animal models have shown that stem cell-based therapies may improve the outcome of the disease, and that mesoangioblasts are promising stem cells in this respect. The efficacy of mesoangioblasts in yielding extensive muscle repair is, however, still limited. We found that mesoangioblasts treated with nitric oxide (NO) donors and injected intra-arterially in ␣-sarcoglycan-null dystrophic mice have a significantly enhanced ability to migrate to dystrophic muscles, to resist their apoptogenic environment and engraft into them, yielding a significant recovery of ␣-sarcolgycan expression. In vitro NO-treated mesoangioblasts displayed an enhanced chemotactic response to myotubes, cytokines and growth factors generated by the dystrophic muscle. In addition, they displayed an increased ability to fuse with myotubes and differentiating myoblasts and to survive when exposed to cytotoxic stimuli similar to those present in the dystrophic muscle. All the effects of NO were cyclic GMP-dependent since they were mimicked by treatment with the membrane permeant cyclic-GMP analogue 8-bromo-cGMP and prevented by inhibiting guanylate cyclase. We conclude that NO donors exert multiple beneficial effects on mesoangioblasts that may be used to increase their efficacy in cell therapy of muscular dystrophies.
mesoangioblasts are not yet known, but it is conceivable that it may arise from a limited homing of these cells to muscle, as well as a reduced ability of these cells to fuse and to resist the cytotoxic environment existing in the damaged muscle, where several pro-inflammatory and pro-apoptotic stimuli may be present (Tews and Goebel, 1996; Rando et al., 1998; Engvall and Wewer, 2003) . To date, no studies have reported specific pharmacological approaches to enhance the therapeutic efficacy of cell therapy, even though we showed that exposure to cytokines such as high mobility group box 1 (HMGB1) and stromal cell-derived factor 1 (SDF-1) increases mesoangioblast colonisation of dystrophic muscle (Palumbo et al., 2004; Galvez et al., 2006) .
A good candidate molecule to increase the efficiency of muscle repair by mesoangioblasts is nitric oxide (NO), a shortlived messenger generated by skeletal muscle to play important roles in regulating its own physiological functions (Wolosker et al., 1997; Bredt, 1998; Balon and Nadler, 1997; Stamler and Meissner, 2001; Eu et al., 2003; Shen et al., 1994; Wang et al., 1995; Clementi and Meldolesi, 1997; Nisoli et al., 2004) . Several pieces of evidence support this idea. NO actively participates in processes important to muscle regeneration, such as the myogenic programme activated by insulin-like growth factor (IGF)-II (Carrasco et al., 2002; Kaliman et al., 1999) or by stimulating myoblast fusion (Pisconti et al., 2006) . In addition, NO contributes to activation of satellite cells by mediating the production of hepatocyte growth factor (HGF) and follistatin (Anderson, 2000; Tatsumi et al., 2002; Pisconti et al., 2006) .
Here, we report that a brief ex-vivo treatment of mesoangioblasts with NO donors enhances their ability to migrate, resist death-inducing stimuli of the type known to be present in dystrophic muscles and fuse with regenerating myofibres. The action of NO is cyclic GMP (cGMP)-dependent and appears to be mediated by classical pathways involved in myogenesis and muscle repair. Our results indicate that the treatment with NO exerts multiple actions that enable mesoangioblasts to limit muscle damage in vivo more efficiently, thus opening an opportunity for improving the efficacy of cell therapy.
Results
NO enhances homing of mesoangioblasts delivered intra-arterially in ␣SG-null mice Mesoangioblasts isolated from the dorsal aorta of wild-type E9.5 C57BL/6 mouse embryos (clone D16) (Minasi et al., 2002) and injected into the femoral artery are able to engraft into muscle and yield both morphological and functional repair in ␣SG-null mice (Duclos et al., 1998; Sampaolesi et al., 2003) .
We investigated whether NO enhanced the therapeutic function of these cells. To this end, mesoangioblasts were cultured for 12 hours in growth medium in the presence or absence of either (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate] (DETA-NO) (20 M) or isosorbide mononitrate (IMN) (50 M), two widely employed, structurally unrelated NO-releasing compounds (Yamamoto and Bing, 2000) . At the concentrations used these NO-donors release concentrations of NO in the physiological range (Clementi et al., 1998) . Mesoangioblasts (5ϫ10 5 per animal) were then washed free of the drugs and injected into the right femoral artery of ␣SG-null mice. Mice were sacrificed 21 days after injection, and the quadriceps, gastrocnemius, soleus and tibialis anterior muscles collected. The expression of ␣SG, an index of wild-type mesoangioblast integration, was then evaluated, by real-time PCR, in quadriceps, gastrocnemius and soleus muscles. Expression of ␣SG in the tibialis anterior was evaluated by western blot analyses and immunohistochemistry. Using this singleinjection protocol the restoration of ␣SG expression by untreated mesoangioblasts was clearly detectable, although lower than that obtained with repeated cell injections (Sampaolesi et al., 2003) . Mesoangioblasts pretreated with DETA-NO or IMN yielded a recovery of ␣SG mRNA levels in the various muscles that was significantly higher than that induced by untreated mesoangioblasts (Fig. 1A) . Accordingly, ␣SG expression analysed by western blotting and immunohistochemistry was also increased (Fig. 1B,C , and data not shown), and the areas in which ␣SG expression was increased by NO-treated mesoangioblasts were larger in size than those observed with untreated mesoangioblasts and contained more ␣SG-positive fibres. In the tibialis anterior the increase in area size was of 26.3±1.3% and 22.7±2.0% with DETA-NO-and IMN-treated mesoangioblasts, respectively (n=15, P<0.01 vs. control). In the same muscle, of a total fibre number of 418±28, the numbers of ␣SG-positive fibres were 109±12, 184±15 and 142±9 after injection with control mesoangioblasts, DETA-NO-and IMN-treated mesoangioblasts, respectively (n=20, IMN-or DETA-NOtreated mesoangioblasts: P<0.01 vs. control). In all these experiments the effect of pretreatment with DETA-NO and IMN was dependent on NO generation because the treatments with the amine DETA or isosorbide did not yield significant effects (data not shown).
The NO-dependent enhancement of mesoangioblast homing in vivo is mediated through cGMP generation A key downstream effector of NO is cGMP, which is generated following activation of the 'soluble', NO-dependent guanylate cyclase (Moncada et al., 1991) . Although mesoangioblasts express none of the NO-synthesizing enzymes, in preliminary experiments they were found to be endowed with the NOdependent guanylate cyclase (data not shown). To examine the cGMP-dependency of the effect of NO, mesoangioblasts were incubated for 12 hours with the cell-permeable analogue of cGMP, 8-bromo-cGMP (8-Br-cGMP) (1 mM), or DETA-NO combined with 1H-(1,2,4) oxadiazolo [4,3-␣]quinoxalin-1-one (ODQ) (1 M), a selective guanylate cyclase inhibitor that prevents NO-dependent cGMP generation (Garthwaite et al., 1995) . Pretreatment of mesoangioblasts with 8-Br-cGMP enhanced ␣SG expression in a manner similar to the pretreatment with the NO donors (Fig. 1A-C) . The combined pretreatment with DETA-NO and ODQ consistently abolished this effect. Pretreatment with ODQ alone did not have significant effects (data not shown). These results indicate that the effect of NO on mesoangioblast homing is cGMPdependent.
Mechanisms through which NO/cGMP increases homing of mesoangioblasts in vivo Various mechanisms may conceivably explain the enhanced therapeutic efficacy of the NO-treated mesoangioblasts, including an increased ability to migrate through vessels and into the site of damage, resist the apoptogenic stimuli present in the dystrophic muscle and fuse with, and repair, existing myofibres. We decided to investigate these mechanisms in vivo separately from each other. To assess chemoattraction and cell movement, green fluorescent protein (GFP)-expressing mesoangioblasts pretreated or not with IMN, DETA-NO, 8-BrcGMP or DETA-NO plus ODQ were injected into the right femoral artery. Mice were sacrificed 6 hours later, and the quadriceps, gastrocnemius and tibialis anterior muscles collected. Also collected were the liver, spleen and lungs, i.e. the filter organs in which mesoangioblasts tend to accumulate when injected intra-arterially (Sampaolesi et al., 2003) . The percentage of cells found in the various muscles and organs was evaluated measuring GFP expression by real-time PCR. Pretreatment with DETA-NO or IMN significantly increased the ability of mesoangioblasts to reach the muscles ( Fig. 2A) and reduced the percentage of mesoangioblasts retained in the filter organs (Fig. 2B) .
To distinguish between the effect of NO on apoptosis and on the ability to reach target muscles, the pretreated mesoangioblasts were injected directly into the right tibialis anterior muscle. Twelve hours later, treated and controlateral (control) muscles were removed and cell death assessed by staining with the TUNEL technique. As shown in Fig. 2C , the dystrophic muscle showed signs of apoptosis and induced apoptosis of injected mesoangioblasts, recognised by their GFP positivity. This apoptosis was clearly reduced if the cells were pretreated with either NO donor before their injection. Treatment with DETA-NO reduced apoptosis by 58±4.9% [n=3, P<0.01 vs not treated (NT)].
To analyse the effect of NO on muscle repair, the pretreated mesoangioblasts were injected directly into the right tibialis anterior muscle as above, but muscles were removed and analysed after 21 days. The pretreatment with either NO donor resulted in a significantly increased expression of ␣SG, measured by both quantitative real-time PCR (Fig. 2D ) and western blot analyses (Fig. 2E ). The fact that restoration of ␣SG levels by untreated mesoangioblasts was reduced compared with that observed with intra-arterially delivered cells (compare NT in Fig. 1B and Fig. 2E ) may reflect an increased cell death due to this specific route of administration (Beauchamp et al., 1999) 
Of importance, the pretreatment with 8-Br-cGMP mimicked the effects of NO on all the mechanisms investigated, while coincubation with DETA-NO and ODQ abolished it ( Fig. 2A-E) . Pretreatment with ODQ alone did not have significant effects on either parameter investigated (data not shown). These results indicate that NO has independent effects that help to enhance homing of mesoangioblasts in a cGMP-dependent manner.
NO/cGMP enhances migration of mesoangioblasts in vitro in response to chemoattractants
We performed different sets of in vitro experiments to investigate in detail the mechanisms of the NO/cGMP effects on mesoangioblast functions observed in vivo. We evaluated the effect of NO/cGMP pretreatment on migration of mesoangioblasts using a transwell system in which the upper and lower chambers were separated by a gelatin-coated cellpermeable membrane. Mesoangioblasts pretreated or not with
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IMN, DETA-NO, 8-Br-cGMP or DETA-NO plus ODQ were plated into the upper chamber and serum-starved overnight. Migration was triggered by the addition of vascular endothelial growth factor (VEGF) (10 ng/ml), a known chemoattractant of these cells, in the lower chamber (Palumbo et al., 2004) , transforming growth factor-␤ (TGF-␤) (100 ng/ml), tumour necrosis factor-␣ (TNF-␣) (10 ng/ml), hepatocyte growth factor (HGF) (10 ng/ml) or basic fibroblast growth factor (bFGF) (10 ng/ml), i.e. chemokines and growth factors known to be present in the environment of the regenerating dystrophic muscle (Charge and Rudnicki, 2004) . Migration was measured after 6 hours and compared with that triggered by bovine serum albumin (BSA) (0.1%), used as a negative control. As shown in Fig. 3A , migration of mesoangioblasts was dependent on the stimulus used, with TGF␤ and TNF␣ being the most powerful chemoattractants, whereas smaller but still significant migration was induced by VEGF, HGF and bFGF. As shown in the graph and representative images of Fig. 3B ,C, pretreatment with either DETA-NO or IMN increased mesoangioblast migration in response to all stimuli used. The effect of NO was mimicked by 8-Br-cGMP and inhibited by ODQ, indicating the cGMP-dependence of the effect of NO. Interestingly, neither NO nor 8-Br-cGMP enhanced migration significantly in the absence of chemoattractants ( Fig. 3B ; data not shown).
We then investigated whether the stimulatory effect of NO/cGMP was still maintained in a transwell migration assay through an endothelial cell layer. To this end mouse microendothelial H5V cells were plated onto the upper membrane of the transwell insert and cultured until they reached confluence. In this assay we used LacZ-expressing mesoangioblasts so that migrated cells were distinguished from endothelial cells by ␤-galactosidase staining. Under these conditions, VEGF, HGF and TNF␣ triggered significant migration of control, untreated mesoangioblasts (Fig. 3D) . Pretreatment with DETA-NO, IMN or 8-Br-cGMP increased migration further. The effect of DETA-NO was abolished when it was administered together with ODQ.
We studied whether differentiated L6E9 myotubes and nondifferentiating L6E9 myoblasts attracted mesoangioblasts and whether NO affected this event. We found that a significant number of mesoangioblasts migrated through the H5V cell monolayer in the presence of myotubes. By contrast, myoblasts failed to trigger migration (Fig. 3E) . Pretreatment with either DETA-NO or IMN further increased mesoangioblast migration triggered by myotubes. The effect of NO was mimicked by 8-Br-cGMP and inhibited by ODQ. Conversely, none of the pretreatments triggered migration towards undifferentiated myoblasts (Fig. 3E ). Of importance, mesoangioblast pretreatment with ODQ alone had no significant effects in any of the migration experiments (data not shown).
Differentiation of mesoangioblasts into skeletal muscle cells is enhanced by NO/cGMP treatment in vitro
When co-cultured with myogenic cells, mesoangioblasts fuse with them and differentiate into skeletal muscle (Minasi et al., 2002) . To investigate the effect of NO on this event we performed two different sets of experiments: in the first mesoangioblasts and L6E9 myoblasts were co-cultured and induced to differentiate together for 5 days (co-fusion experiments), whereas in the second mesoangioblasts were co-cultured with preformed L6E9 myotubes (post-fusion experiments). Cells were fixed and stained with the antimyosin heavy-chain monoclonal antibody (mAb) MF20 to identify myotubes and differentiated myocytes and with 4Ј,6- diamidino-2-phenylindole (DAPI). The DAPI staining allowed us to distinguish between rat nuclei (L6E9 cells) and mouse nuclei (mesoangioblasts) on the basis of the different heterochromatin distribution (Blau et al., 1983) . Pretreatment of mesoangioblasts with DETA-NO, IMN or 8-Br-cGMP increased their ability to fuse to both myoblasts and myotubes. The effect of DETA-NO was no longer observed in the presence of ODQ (Fig. 3F,G) . ODQ had no effects on the fusogenic ability of mesoangioblasts when administered alone (data not shown).
NO/cGMP treatment inhibits death of mesoangioblasts induced by different stimuli in vitro NO, when generated at low concentrations often increases cell resistance to apoptosis, an effect that may persist even after its removal (Liu and Stamler, 1999; Falcone et al., 2004; Perrotta et al., 2004) . We investigated whether NO/cGMP had pro-survival effects on mesoangioblasts. To this end, mesoangioblasts pretreated or not with DETA-NO, IMN, 8-BrcGMP or DETA-NO plus ODQ were exposed for a further 24 hours to cytotoxic stimuli known to be present in the microenvironment of the dystrophic muscle, i.e. TNF␣ (100 ng/ml) and the reactive oxygen species generating agents H 2 O 2 (100 M) and As 2 O 3 (20 M) (Tews and Goebel, 1996; Rando et al., 1998; Emery, 2002; Engvall and Wewer, 2003; Hodgetts et al., 2003) . Cell death was determined 24 hours later by measuring both Annexin V staining of phosphatidylserine exposed on the outer leaflet of the plasma membrane and propidium iodide (PI) incorporation. Results obtained are summarised in Fig. 4A , and representative dot-plot analyses showing the results using As 2 O 3 as the death-inducing stimulus are shown in Fig. 4B . Cell death-induction by all stimuli used was prevented by pretreatment with either NO donor or 8-BrcGMP and restored by co-incubation of DETA-NO with ODQ (Fig. 4A,B) . We then assessed whether NO protected against cell-mediated cytotoxicity, an event known to occur in the damaged, dystrophic muscle (Hohlfeld and Engel, 1990) . To this end, mesoangioblasts, after the various pretreatments indicated above, were stained with the green fluorescent dye 5-chloromethylfluorescein (CFMDA) and then co-incubated for 16 hours with cytotoxic T lymphocytes. The results obtained show that NO conferred protection against cytotoxicity, evaluated by measuring PI incorporation (Fischer et al., 2002) (Fig. 4C) . Also in this case, the effect of NO depended on cGMP generation.
Expression-profile analysis shows that NO increases expression of specific genes in mesoangioblasts We investigated whether the effects of NO on mesoangioblast function described in this study involved a change in the expression of specific genes. Mesoangioblasts were pretreated with or without DETA-NO, as above, and their geneexpression profile analysed by microarray analysis. Fluorescent-labelled cRNA was hybridized to the Affymetrix Murine Genome MOE430 GeneChip arrays. From this first analysis and from a reverse transcription (RT)-PCR validation assay we found that NO did not cause profound changes in the overall profile of gene expression, but the expression of specific genes that may explain its effects on mesoangioblasts was affected (Table 1 ). In particular, NO increased the expression of follistatin, insulin-like growth factor I (IGF-I) and Journal of Cell Science 119 (24) metalloproteases, all involved in the network of events governing myoblast fusion and differentiation (Tatsumi et al., 2002; Horsley and Pavlath, 2004; Iezzi et al., 2004) . In addition, the pretreatment with NO increased the expression of receptors for HGF, VEGF and TNF␣, as well as members of families of adhesion molecules known to play a role in migration, such as cadherins and integrins (Carmeli et al., 2004; Horsley and Pavlath, 2004; Krauss et al., 2005) . Finally, NO increased the expression of two anti-apoptotic members of the Bcl protein family, Bcl-2 and Bcl-xL, and reduced the expression of pro-apoptotic Bax (Adams et al., 2001 ).
Discussion
A previous study using mesoangioblasts showed that these stem cells have therapeutic efficacy in the ␣SG-null mouse (Sampaolesi et al., 2003) , a model of Duchenne muscular dystrophy (Duclos et al., 1998 ). Here we show that a brief exvivo treatment of mesoangioblasts with NO significantly increases various independent parameters important for their therapeutic activity, i.e. the ability to reach dystrophic muscles, to resist their apoptogenic environment and to engraft into them. The combination of these effects resulted in increased efficiency in homing of intra-arterially delivered mesoangioblasts that yielded an enhanced structural recovery of the damaged muscle. Of importance, the increased homing of mesoangioblasts to the muscle was accompanied by a concomitant reduction in their number in the relevant filter organs. This number is large and may cause damage to these organs . Thus, increasing homing to the target tissue has two positive outcomes, the delivery of more cells to repair the target tissue and a reduction in the number of cells that are trapped in filter organs.
The treatment with NO shows two characteristics. First, it is persistent, since a brief exposure of mesoangioblasts yielded a long-lasting increase in their function; second, it depends on the generation of cGMP following activation of guanylate cyclase, an enzyme known to be stimulated by nanomolar concentrations of NO and to mediate physiological actions of the gas (Moncada et al., 1991) . Both these characteristics are crucial from a therapeutic standpoint because the amelioration of mesoangioblast function was obtained with a short-term drug exposure, compatible with minimal manipulation of cells ex vivo, and with concentrations of NO in the physiological range.
Using in vitro experiments, we studied in further detail the mechanisms responsible for the beneficial effects of NO observed in vivo. We investigated the effect of NO on migration of mesoangioblasts towards multinucleated myotubes. These experiments were performed in the presence of an endothelial cell layer in a transwell system, an assay commonly used to examine the chemotactic properties of specific molecules, and proven as a reliable indicator of the mechanisms that govern cellular trafficking in vivo . Moreover, this in vitro setting mimicks the microenvironment encountered by mesoangioblasts after intraarterial injection, since myotubes correspond to newly regenerated, immature fibres (Charge and Rudnicki, 2004) . We found that pretreatment with NO significantly increased migration of mesoangioblasts towards myotubes. Interestingly, in control experiments using proliferating myoblasts, migration of mesoangioblasts was almost undetectable and not significantly modified by NO, suggesting that some factors secreted by newly-formed muscle fibres stimulate mesoangioblast migration and synergise with the action of NO.
We also investigated the ability of NO to ameliorate mesoangioblast migration triggered by cytokines and growth factors known to be produced in the pro-inflammatory environment of the regenerating dystrophic muscle, such as TNF␣, HGF, bFGF and TGF␤ (Charge and Rudnicki, 2004; Wagers and Conboy, 2005) or VEGF, a chemoattractant for mesoangioblasts (Palumbo et al., 2004) . NO significantly increased mesoangioblast migration triggered by all of these chemoattractants, both in the presence and absence of an endothelial cell layer. Of importance, all the effects of NO in these in vitro assays were found to be cGMP-dependent, consistent with the in vivo migration results. The fact that NO increases migration triggered by myotubes and a variety of chemoattractants is of relevance for the therapy of muscular dystrophy, since it indicates that the beneficial actions of NO apply to the various pro-inflammatory conditions that may arise during the course of the disease.
An important aspect of damaged muscle is that it originates a pro-apoptotic microenvironment in which cytokines such as TNF␣, oxidative stress and immune-competent cells play a role, and that may contribute to the poor outcome of transplantation of myogenic cells (Tews and Goebel, 1996; Rando et al., 1998; Emery, 2002; Engvall and Wewer, 2003; Hohlfeld and Engel, 1990; Hodgetts et al., 2003) . In vivo, we found that NO/cGMP reduced the number of apoptotic mesoangioblasts observed in muscle sections; in vitro, the exposure to NO/cGMP increases the ability of mesoangioblasts to resist the apoptogenic effects of TNF␣, reactive oxygen species and cytotoxic T lymphocytes. This evidence supports the fact that NO protects mesoangioblasts from apoptosis, consistent with its cGMP-dependent anti-apoptotic role described for other cell types (Liu and Stamler, 1999) .
The observation that injection of NO-pretreated mesoangioblasts led to a recovery of ␣SG expression by muscle fibres suggests an additional mechanism that may contribute to the in vivo effect of NO is an increased mesoangioblast ability to fuse to pre-existing myofibres. A role for NO in myoblast fusion has indeed been shown by some studies (Kaliman et al., 1999; Pisconti et al., 2006) , although whether this also applies to mesoangioblasts is not known. To investigate this possibility we used an in vitro fusion assay in which mesoangioblasts were co-incubated with either preformed myotubes or differentiating myoblasts. Pretreatment
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with NO led to increased fusion of mesoangioblasts in both types of assays. Also in this case the effect was cGMPdependent, and therefore consistent with the in vivo results.
Signalling events activated by the NO/cGMP pathway are multiple and comprise both short-term modifications of protein function and activity and long-term effects on gene transcription (Pilz and Casteel, 2003) . The persistency of the effect of NO/cGMP on mesoangioblasts observed here is consistent with the latter mechanism of action. Moreover, induction and repression of specific genes is also crucial in the process of myogenesis, myoblast fusion and muscle repair (Buckingham, 2001; Charge and Rudnicki, 2004; Cossu and Biressi, 2005) . We have therefore investigated whether regulation of gene transcription explained the effects of NO/cGMP on mesoangioblasts. We found that NO increased expression by mesoangioblasts of several plasma membrane receptors known to play key roles in myogenesis, such as members of metalloproteases and disintegrin families, adhesions molecules, integrins and cadherins (Carmeli et al., 2004; Horsley and Pavlath, 2004; Krauss et al., 2005) . NO also increased the expression of HGF, which participates in NOinduced satellite cell activation (Anderson, 2000; Tatsumi et al., 2002) , and of IGF-I and follistatin, which contribute to muscle hypertrophy (Glass, 2003; Iezzi et al., 2004) , the latter recently shown to mediate NO-induced satellite cell fusion (Pisconti et al., 2006) . Interestingly, NO also increased the expression of receptors for chemoattractants, and this, together with the effect on adhesion molecules, may explain why NOtreated mesoangioblasts are endowed with and increased migratory ability. NO also inhibited the mesoangioblast expression of proapoptotic Bax, while increasing the expression of anti-apoptotic Bcl-2 and Bcl-xL (Adams et al., 2001) . This, together with the observation that the antiapoptotic action of NO was not restricted to a specific stimulus, strongly suggests that NO switches off the apoptotic programme elicited by the damaged muscle environment in mesoangioblasts, rather than acting as a simple negative modulator of selected apoptotic signals. Although the changes in the levels of expression of the various genes investigated were not striking, the pattern of modifications induced in mesoangioblasts by NO/cGMP is consistent with a general switch on of signalling pathways involved in myogenesis and muscle repair. How and to what extent the changes in gene expression are integrated in shaping the enhanced function of NO-treated mesoangioblasts remains to be investigated.
Which among the various effects of NO on mesoangioblasts described here is the most relevant in in vivo conditions is difficult to predict, and enhanced migration, resistance to apoptosis and ability to fuse may conceivably all play a role. However, the anti-apoptotic effect of NO is the most dramatic in terms of fold changes and has already been shown to play a key role with other cell types in vivo . This strongly suggests that protection against apoptosis plays a crucial role in determining the NO-dependent enhanced homing of mesoangioblasts.
In conclusion, we propose that the treatment of mesoangioblasts with NO significantly enhances their homing to dystrophic muscle, yielding a recovery of its function. Since this treatment does not require extensive cell manipulation and is non-toxic it appears worth pursuing, especially in view of the new NO donors and compounds able to increase cGMP concentration that are currently undergoing validation for clinical use (Burgaud et al., 2002; Nakane, 2003) . In addition, because of its simplicity, the treatment might be easily combined with other strategies to yield an enhanced therapeutic effect combining increased mesoangioblast survival and ability to reach damaged muscles and engraft into them. Finally, this therapeutic approach may be helpful not only in muscular dystrophies but also in other pathological states in which stem cell therapy has been proposed, including congenital myopathies and muscle atrophy (Wagers and Conboy, 2005) .
Materials and Methods

Reagents
Cell culture reagents were purchased from Cambrex (Verviers, Belgium); the antisarcomeric myosin MF20 and anti-␣SG mAbs from DSHB (University of Iowa, Iowa City, IA, USA) and NovoCastra (Newcastle, UK), respectively. In immunoblot and immunohistochemistry analyses primary Abs were detected by appropriate secondary Abs conjugated with horseradish peroxidase (BioRad, Hercules, CA, USA) or Alexa-Fluor 488 and 594, respectively (Molecular Probes, Eugene, OR, USA). Polycarbonate membrane transwell inserts used for the in vitro chemotaxis assays were purchased from Costar (Milan, Italy); mouse VEGF, TNF-␣, HGF, bFGF and TGF-␤ from R&D Systems (Abingdon, UK); and fluorescein isothiocyanate (FITC)-Annexin V and PI from Bender MedSystem (Vienna, Austria). The reagents for RNA extraction and cDNA preparation were obtained by Invitrogen Life Technologies (Carlsbad, CA, USA). ODQ and DETA-NO were from Alexis Italia (Florence, Italy), and all the other reagents were purchased from Sigma (Milan, Italy).
Animals
␣SG-null C57BL/6 mice were a kind gift of K. Campbell (Iowa University, Iowa City, IA, USA). Animals were housed in the pathogen-free facility at our institution and treated in accordance with the European Community guidelines, and with the approval of the Institutional Ethical Committee. Animals were used when 4 months old, since at this stage ␣SG-null mice are characterized by the development of histopathological features of muscle dystrophy with ongoing fibre degeneration and modest spontaneous regeneration (Duclos et al., 1998) .
Cell culture
Wild-type, GFP-or LacZ-expressing D16 mesoangioblasts were generated and cultured as described (Minasi et al., 2002; Sampaolesi et al., 2003; Palumbo et al., 2004) . In all experiments the pretreatment of mesoangioblasts with DETA-NO (20 M), IMN (50 M), 8-Br-cGMP (1 mM), ODQ (1 M) or DETA-NO plus ODQ was for 12 hours, after which cells were washed free of the drugs and suspended in culture medium. Delivery of mesoangioblasts was either by intra-arterial injection through the right femoral artery with 5ϫ10 5 mesoangioblasts per animal, performed exactly as described (Sampaolesi et al., 2003) , or by injection of 5ϫ10 5 cells directly into tibialis anterior muscles.
The rat skeletal muscle cell line L6E9 was cultured in Dulbecco's modified Eagle's medium (DMEM) containing 15% foetal bovine serum (FBS), 200 M glutamine, 1000 U/ml penicillin and streptomycin growth medium (GM). Differentiation was obtained by shift to a differentiation medium (DM) containing 2% horse serum. The microendothelium cell line H5V (a kind gift of Elisabetta Dejana, University of Milano, Milan, Italy) was cultured in DMEM containing 10% FBS, 200 M glutamine, 1000 U/ml penicillin and streptomycin.
Quantitative real-time PCR analysis
Tissue samples were homogenized and RNA extracted using TRIzol reagent (Invitrogen) and reverse transcribed into complementary DNA by using a Taqman kit (Platinum Taq DNA polymerase; Invitrogen). Real-time quantitative PCR analyses were performed using a Mx3000P real-time PCR detection system (Stratagene, La Jolla, CA, USA). Each cDNA sample was amplified in duplicate by using the SYBR Green Supermix (BioRad) for GFP (GFP primers: forward (FW), 5Ј-AAGTTCATCTGCACCACCG-3Ј; reverse (Rev) , 5Ј-TCCTTGAAGAAGATG -GT GCG-3Ј). Data are expressed as the percentage of migrated cells, which is calculated by comparing the level of GFP messenger in our sample with that corresponding to the total input of injected cells. Real-time PCR analyses of ␣SG expression were performed using the Taqman Universal PCR master mixture containing AmpliTaq Gold DNA with commercial primers (Applied Biosystems, Foster City, CA, USA) for ␣SG detection. For Taqman assays, the level of ␣SG measured represents the specific signal detected in the sample from mesoangioblastinjected ␣SG-null mouse muscles vs. that of a positive control for ␣SG expression (corresponding wild-type mouse muscles).
Protein extraction and immunoblot analysis
Muscle tissues were dissected and homogenized in 100 mM NaHCO 3 , 1 mM EDTA, 2% sodium dodecyl sulphate and protease inhibitor cocktail (Complete, Roche Diagnostics) and centrifuged (1000 g) for 10 minutes at 4°C to discard cellular debris. Sample preparation and western blot analyses were performed as described (Bulotta et al., 2001 ).
Immunohistochemistry
Tibialis muscles recovered from the mesoangioblast-injected animals were dissected and frozen in liquid N 2 -cooled isopentane. Serial muscle sections were immunostained as previously described (Sampaolesi et al., 2003) with the anti-GFP, anti-laminin or anti-␣SG Abs. Primary Abs were detected using appropriate secondary Abs and nuclei were visualized with the DNA dye DAPI. Quantification of ␣SG-positive areas and fibre number was performed in five randomly selected fields of at least three non-adjacent transverse ␣SG-laminin double-stained sections along the longitudinal axis of the muscle.
Differentiation experiments
L6E9 myoblasts were plated in growth medium at a density of 1.5ϫ10 5 and shifted in DM medium 24 hours later. D16 mesoangioblasts suspended in DM were added to L6E9 cultures either at the moment of medium shift (5ϫ10 4 cells/dish, co-fusion experiments) or after 3 days (2ϫ10 4 cells/dish, post-fusion experiments), i.e. when L6E9 myotubes were already formed.
After 5 days of co-culture, the medium was removed, the cells fixed and myotubes and nuclei revealed by immunofluorescence using the anti-myosin heavy-chain Ab (MF20, 1:3) and DAPI, respectively . The percentage of mesoangioblasts fused to rat myotubes was measured by counting the number of mouse nuclei in myosin heavy chain-stained rat fibres (5-8 random fields for each sample) on the basis of different staining with DAPI because of different heterochromatin distribution.
Migration assays
LacZ-expressing D16 mesoangioblasts (2ϫ10 4 ) were plated in complete medium in the upper chamber of transwell inserts (membrane diameter: 6.5 mm; pore size: 8 m) coated with type A gelatin from porcine skin. At the end of the pretreatments the cells were starved overnight in DMEM without serum. The following morning the lower chamber medium was substituted with DMEM containing differentiated L6E9 myotubes, undifferentiated L6E9 cells or one of the following chemotactic agents: TGF␤ (100 ng/ml), VEGF (10 ng/ml), TNF␣ (10 ng/ml), HGF (10 ng/ml) or bFGF (10 ng/ml). In the transmigration experiments through endothelium, mouse microendothelial H5V cells were plated on the gelatin-coated transwell membrane (1ϫ10 4 cells/dish) and grown in DMEM containing 10% FBS until they reached confluence, before the addition of mesoangioblasts. The tightness of the monolayers was checked by measuring the diffusion of BSA from the upper to the lower chamber. The number of mesoangioblasts that crossed the membrane pores was evaluated after 6 hours. To this end, non-migrated cells were mechanically removed from the upper side of the transwell system, whereas the cells in the lower side of the filter membrane were fixed in 4% paraformaldehyde for 10 minutes at 4°C and stained with crystal violet [0.1% in methanol-water (2:8) solution for 20 minutes at room temperature]. The number of migrated cells was measured using an inverted microscope and by counting 5-10 random fields of the lower face of the transwell membrane at 20ϫ magnification or by X-Gal staining, performed according to standard protocols (Brunelli et al., 2003) . Migration index was calculated by dividing the number of migrated cells in the presence of the chemotactic agents by the cells migrated in response to DMEM with 0.1% BSA (control).
Cell death experiments
After the various pretreatments, mesoangioblasts were incubated with or without TNF␣ (100 ng/ml), H 2 O 2 (100 M) or As 2 O 3 (20 M) for 24 hours. Cells were detached and stained with FITC-Annexin V and PI according to the manufacturer's instructions and analysed by flow cytometry as described (Sciorati et al., 1997) . Cells showing single staining for Annexin V or double staining for Annexin V and PI were considered dead cells. To study the effect of cytotoxic T lymphocytes, 5ϫ10 4 mesoangioblasts or control cells (splenocytes and RMA cells) were stained with the vital green fluorescent dye CFMDA and incubated with increasing numbers of cytotoxic effector T cells (1:1, 1:5, 1:10, 1:25) (Ferrarini et al., 1999) . Cell death was evaluated by flow cytometry measuring PI incorporation after 16 hours (Fischer et al., 2002) .
Gene expression profiling
Biotin-labelled target synthesis as well as the Affymetrix Mouse Genome MOE430 GeneChip array hybridization and scanning were performed with Affymetrix instruments and by applying standard procedures and protocols on total RNA isolated from cultured cells using the RNeasy RNA isolation kit (Qiagen, Valencia, CA, USA). The amount of a transcript mRNA (signal) was determined using the GCOS 1.2 absolute analysis algorithm as already described (Liu et al., 2002) .
